AI filing briefs · archive
Every 8-K brief, with filters
The whole archive: 33,614 AI briefs of material SEC Form 8-K filings by 4,788 companies: 2,228 written within three weeks of the filing (filed since Oct 19, 2026) and 31,386 written later, for past filings. Pick a month, or filter by date, 8-K item, tone, impact, topic or ticker.
Briefs on record33,614every one kept
Companies4,788with at least one brief
Recent filings2,228filed since Oct 19, 2026
Past filings31,386written later, in Nov 2026
Hallador Energy reported third-quarter 2026 results with total revenue of $130.3 million, down 11% from a year earlier but up 28% from the second quarter. The company posted a net loss of $4.5 million, compared with net income of $23.9 million a year earlier, and total debt rose to $551.9 million after a $600 million construction bridge loan tied to its Turtle Creek gas project, which it targets for a final investment decision before the end of 2026.
- Q3 2026 total revenue was $130.3 million, down from $146.6 million in Q3 2025 and up from $101.5 million in Q2 2026.
- Net loss was $4.5 million, versus net income of $23.9 million in Q3 2025 and a net loss of $15.2 million in Q2 2026.
- Adjusted EBITDA was $17.3 million, compared with $24.9 million in Q3 2025.
- Total debt rose to $551.9 million at September 30, 2026, from $45.0 million at June 30, 2026, after a $600 million senior secured construction bridge loan facility.
Read the filing on SEC.gov ↗
Douglas Elliman reported third-quarter 2026 net income of $7.4 million, or $0.08 per diluted share, compared with a net loss of $24.7 million a year earlier, while revenue fell to $252.1 million from $262.8 million. Adjusted EBITDA was a $5.3 million loss versus $1.0 million of income, and the company also approved a $10 million share repurchase program, which it says will be funded from cash on hand.
- Q3 2026 revenue was $252.1 million vs. $262.8 million in Q3 2025; the company sold its property management business in October 2025.
- Q3 operating income was $6.3 million vs. an operating loss of $10.7 million; Adjusted EBITDA was a $5.3 million loss vs. $1.0 million of income.
- Nine-month revenue was $749.9 million vs. $787.6 million, and the net loss narrowed to $11.6 million ($0.14 per share) from $53.3 million ($0.63 per share).
- The Board approved a $10 million share repurchase program; cash and a Treasury bill totaled about $123 million with no long-term debt as of September 30, 2026.
Read the filing on SEC.gov ↗
Microvast reported third-quarter 2026 revenue of $45.8 million, down 62.8% from $123.3 million a year earlier, and a net loss of $76.8 million, including $35.7 million of non-cash impairment charges. The company said its available cash is expected to be insufficient to meet obligations over the next twelve months, and its going concern doubt has not been alleviated, so shareholders face significant uncertainty about refinancing its debt.
- Q3 2026 revenue was $45.8 million versus $123.3 million in Q3 2025; gross margin fell to 5.2% from 37.6%.
- Q3 2026 net loss was $76.8 million, compared with a net loss of $1.5 million in Q3 2025.
- Cash, cash equivalents and restricted cash were $124.4 million at September 30, 2026; $41.7 million of convertible bonds are due on or before January 31, 2027.
- Net cash used in operating activities was $65.4 million for the nine months ended September 30, 2026.
Read the filing on SEC.gov ↗
Rani Therapeutics reported third-quarter 2026 results with contract revenue of $1.7 million, up from none a year earlier, mainly from its Chugai collaboration. Net loss rose to $8.8 million from $7.9 million as research and development and general and administrative expenses increased, and cash, cash equivalents and marketable securities fell to $45.3 million, which the company says will fund operations at least through the end of 2027.
- Contract revenue was $1.7 million for the quarter ended September 30, 2026, versus no contract revenue a year earlier.
- Net loss attributable to Rani was $7.7 million, compared with $5.4 million in the prior-year quarter; net loss per Class A share was $0.04, versus $0.12.
- Cash, cash equivalents and marketable securities were $45.3 million at September 30, 2026, down from $53.4 million at June 30, 2026.
- In October 2026 the RaniPill platform was accepted into the FDA's Emerging Technology Program; RT-114 expansion cohort data are expected by the end of 2026.
Read the filing on SEC.gov ↗
Bain Capital Specialty Finance (BCSF) reported third-quarter 2026 net investment income of $27.7 million, or $0.43 per share, down from $28.6 million, or $0.44 per share, in the second quarter. Net increase in net assets from operations rose to $0.26 per share from $0.22, while net asset value per share fell to $16.49 from $16.65. The company also declared a fourth-quarter dividend of $0.42 per share and appointed Amrit Kanwal as an independent director, expanding the board to nine members.
- Q3 2026 net investment income was $27.7 million, or $0.43 per share, versus $28.6 million, or $0.44 per share, in Q2 2026; total investment income was $59.9 million, versus $62.3 million.
- Net increase in net assets from operations was $16.7 million, or $0.26 per share, versus $0.22 per share in Q2 2026; net asset value per share was $16.49 at September 30, 2026, versus $16.65 at June 30, 2026.
- Board declared a fourth-quarter 2026 dividend of $0.42 per share, with a record date of December 15, 2026 and payment on or before December 29, 2026.
- Amrit Kanwal, 61, was appointed an independent Class III director effective November 4, 2026, and joined the Audit, Nominating and Corporate Governance, and Compensation Committees.
Read the filing on SEC.gov ↗
Nine Energy Service reported third quarter 2026 revenue of $142.0 million, essentially unchanged from the second quarter's $141.8 million. Net loss widened to $5.1 million, or $(0.36) per share, from $4.9 million, or $(0.35) per share, and adjusted EBITDA fell to $8.3 million from $8.6 million. For shareholders, the company expects fourth quarter revenue to be flat and profitability to be modestly higher than the third quarter.
- Q3 2026 revenue of $142.0 million versus $141.8 million in Q2 2026; cementing revenue rose 11% quarter over quarter.
- Net loss of $5.1 million ($0.36 per share) in Q3 2026 versus $4.9 million ($0.35 per share) in Q2 2026.
- Adjusted EBITDA of $8.3 million in Q3 2026 versus $8.6 million in Q2 2026.
- Management expects Q4 2026 revenue to be flat and profitability to be modestly higher than Q3; total liquidity was $46.0 million at September 30, 2026.
Read the filing on SEC.gov ↗
Exodus Movement reported third quarter 2026 revenue of $32.5 million, up 7% from $30.3 million a year earlier, but swung to a net loss of $8.3 million attributable to the company from net income of $17.0 million in the prior-year quarter. General and administrative expenses rose 94% to $28.9 million, and the company said it expects to cut combined annual costs by about $30 million going into 2027 following the Monavate and Baanx acquisitions.
- Q3 2026 revenue was $32.5 million, up 7% from $30.3 million in Q3 2025
- Net loss attributable to Exodus was $8.3 million, versus net income of $17.0 million a year earlier
- Adjusted EBITDA was a loss of $3.9 million, compared with positive $5.9 million in Q3 2025
- Exodus is on track to reduce combined annual costs by about $30 million going into 2027
Read the filing on SEC.gov ↗
EquipmentShare reported third-quarter 2026 results for the period ended September 30, 2026, with total revenue up 55% year over year to $1,468 million and net income of $20 million, compared with $6 million a year earlier. Adjusted Core EBITDA rose 40% to $594 million, and management said it is confident in its full-year 2026 outlook and sees an opportunity to outperform it. For shareholders, both headline revenue and profit grew, though GAAP net income remains small relative to revenue and interest expense was $88 million in the quarter.
- Total revenue rose 55% to $1,468 million from $945 million; Rental Segment revenue rose 49% to $1,113 million.
- Net income was $20 million versus $6 million; Adjusted Net Income, which excludes $26 million of IPO Founders Awards stock compensation, was $46 million.
- Adjusted Core EBITDA increased 40% to $594 million; net leverage fell to 3.4x from 3.7x a year earlier.
- Current 2026 guidance ranges include total revenue of $5,808 million to $6,045 million and Adjusted Core EBITDA of $2,136 million to $2,224 million.
Read the filing on SEC.gov ↗
Novanta reported third quarter 2026 results on November 9, 2026. GAAP revenue rose 23% to $305 million, while GAAP net income fell to $2 million from $10.7 million and GAAP diluted EPS fell to $0.05 from $0.30. The company also updated its full-year 2026 outlook, now expecting GAAP revenue of $1,135 million to $1,140 million, and said it closed its largest acquisition in company history, Riverpoint Medical.
- Q3 2026 GAAP revenue was $305 million, up 23.1% from $247.8 million; Adjusted EBITDA rose 38.3% to $80.3 million.
- GAAP operating income was $13.9 million versus $21.8 million a year earlier, and restructuring, acquisition, and related costs were $23.1 million.
- Adjusted diluted EPS was $1.05, up 20.7% from $0.87; operating cash flow was $39.3 million versus $8.5 million.
- For full-year 2026, the company now expects GAAP revenue of $1,135 million to $1,140 million and Adjusted EBITDA of $274 million to $277 million.
Read the filing on SEC.gov ↗
Elmet Group reported third-quarter 2026 results for the period ended October 2, 2026, with revenue up 55.6% to $79.6 million and net income of $8.3 million, or $0.24 per diluted share, compared with $1.6 million, or $0.08, a year earlier. Gross margin rose to 31.3% and open order backlog reached a company record $347.4 million, though nine-month net income fell to $3.5 million from $4.0 million and the release gives no new guidance.
- Q3 revenue was $79.6 million versus $51.1 million a year earlier; gross profit margin was 31.3% versus 21.7%.
- Adjusted EBITDA was $17.0 million, or 21.3% of revenue, versus $7.4 million, or 14.5%, in Q3 2025.
- Q3 net income was $8.3 million, or $0.24 per diluted share, versus $0.08 per diluted share a year earlier.
- Nine-month net income was $3.5 million, or $0.10 per diluted share, versus $4.0 million, or $0.20, for the nine months ended September 30, 2025.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.